Ellicott City, MD – The Society for Clinical Research Sites (SCRS) announces Acurian as the corporate sponsor for the SCRS Ambassador Program in Poland. The SCRS Site Ambassador Program brings SCRS benefits to sites in countries around the world. SCRS currently has site members in 49 countries. Countries (in some cases, regions) with an SCRS Site Ambassador receive quarterly SCRS seminars focused on the interests of sites in that area. “Acurian has taken a leadership position in the Ambassador Program by supporting our efforts in Poland,” said Christine Pierre, President of SCRS. “We look forward to supporting site sustainability in Poland and around the world as the SCRS Ambassador Program grows.” “We recognize that sites in Poland are increasingly crucial partners in the effort to successfully enroll global clinical trial programs we support,” said Todd Albin, Senior Director of Site Enrollment Optimization at Acurian, a subsidiary of PPD, a leading global contract research organization. “SCRS has been the global leader in advocating for the sustainability of sites throughout the world. We are very excited to be part of this ambassador program and help introduce Polish sites to SCRS and Acurian so that they can benefit from the variety of ways both of our organizations contribute to their long-term success.” About SCRS SCRS is a global trade organization founded in 2012 which represents over 3,000 research sites in 49 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About Acurian Acurian, a subsidiary of PPD, is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time. For more information, visit www.acurian.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.